MELBOURNE, Australia--(BUSINESS WIRE)--HealthLinx Limited (ASX:HTX) today announced the signing of a joint patent agreement with Bruker Daltonics Inc. to further develop biomarkers that have been discovered under an existing collaboration between the two life science companies. These biomarkers are candidates for a number of pregnancy complications based on scientific research using Bruker Daltonics’ ClinProt™ platform. Associate Professor Greg Rice of HealthLinx and Dr. Gongyi Shi from Bruker Daltonics’ Fremont, California, USA applications laboratory discovered the biomarkers as a result of the two companies’ on-going collaboration and, accordingly, both will be recognised as co-inventors.
